Companies · Pharma

Pharma-Labs Finance LLC

PHOENIX · Pharma · refined from filed group “Other”

Diligence memoA one-page analyst read on Pharma-Labs Finance LLC — recommendation, valuation, rhythm, risks.→
$3.0M
Total raised · real
1
Rounds
—
Latest step-up
Top 52%
Sector rank · raised
Seed
Latest stage · inferred · Mon Jun 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Pharma-Labs Finance LLC looks over-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 2.01× the median modeled value of Seed Pharma companies in 2019–2021 (20 peers) — value vs value, same stage and era.
Dormant
  • Last raise 6.0 yr ago; this sector typically re-raises about every 16 months.
  • Only one round on record and long silent — often defunct, acquired, or gone quiet.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

Pharma-Labs Finance LLC behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
6.3 yr record
Peak capital year was 2020 with $3.0M across 1 filings.
Market position
ahead of 49% of Pharma peers
Capital scale is ahead of 49% of Pharma peers; modeled value is above 69% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Consistent
Canonical totals and visible filing detail are broadly aligned.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2020: $3.0M across 1 filings.
  • Largest single filing was $3.0M on 2020-06-29.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharma

Pharma-Labs Finance LLC is one of 310 Pharma companies tracked from PHOENIX. By capital raised it ranks mid-pack (ahead of 49% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

pharma

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
6
Investors (latest)
2020
Year incorporated
2020-06-29
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MSeed · 2020-06-29 Raised $3.0M (real) Modeled valuation $115M (est)$3.0M$115MSeed2020

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$3.0M · 2020

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$114.6M
Base estimate est.
$2.3M
Conservative case
$898.8M
Upside case
$15.1M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Seed — a $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Model inputs · modeled:benchmark-stage-stepup-v1
20%
Dilution assumption
Implied ownership sold in the financing.
34%
Survival probability
15% low · 52% high
1.68×/yr
Annual markup
2.20×/yr upside case
6.0 yr
Elapsed time used
6.0 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
—
Avg between rounds
—
Capital velocity
6.3 yr
On record since
2020
First round
1
Rounds on file
How it compares to the market

Benchmarked against 310 companies in Pharma. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages)▼ 0.5× of median
This company$3.0M
Sector median$6.4M
Latest round — vs other Seed rounds in sector (real $, this stage)▲ 1.6× above median
This company$3.0M
Sector median$1.9M
Modeled value — vs sector median (estimate, all stages)▲ 1.8× above median
This company$114.6M
Sector median$62.5M

Raised more than 49% of sector peers (real $). Modeled value above 69% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #2 of 20.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0MCapital raised (log)Zoo Pharma Dynamics Inc. · Seed Raised $3.7M · modeled $139.3M (est)FSD Pharma Inc. · Seed Raised $2.6M · modeled $99.9M (est)Deepbiome Therapeutics, Inc. · Seed Raised $2.5M · modeled $95.3M (est)Pykus Therapeutics, Inc. · Seed Raised $2.5M · modeled $73.0M (est)Nexosome Oncology Holdings, Inc. · Seed Raised $3.7M · modeled $69.0M (est)BreStem Therapeutics, Inc. · Seed Raised $3.0M · modeled $68.9M (est)Ten63 Therapeutics, Inc. · Seed Raised $2.1M · modeled $62.5M (est)Plato BioPharma, Inc. · Seed Raised $3.6M · modeled $59.3M (est)Silver Therapeutics, Inc. · Seed Raised $1.5M · modeled $57.1M (est)Javelin Oncology, Inc. · Seed Raised $1.5M · modeled $57.1M (est)Small Pharma Ltd. · Seed Raised $1.9M · modeled $52.8M (est)Pharma-Labs Finance LLC (this company) Raised $3.0M · modeled $114.6M (est)Pharma-Labs Finance LLC
CompanyStageRaised · realValue · estvs peer med.
Zoo Pharma Dynamics Inc.Seed$3.7M$139.3M2.44×
Pharma-Labs Finance LLC this companySeed$3.0M$114.6M2.01×
FSD Pharma Inc.Seed$2.6M$99.9M1.75×
Deepbiome Therapeutics, Inc.Seed$2.5M$95.3M1.67×
Pykus Therapeutics, Inc.Seed$2.5M$73.0M1.28×
Nexosome Oncology Holdings, Inc.Seed$3.7M$69.0M1.21×
BreStem Therapeutics, Inc.Seed$3.0M$68.9M1.21×
Ten63 Therapeutics, Inc.Seed$2.1M$62.5M1.10×
Plato BioPharma, Inc.Seed$3.6M$59.3M1.04×
Silver Therapeutics, Inc.Seed$1.5M$57.1M1.00×
Javelin Oncology, Inc.Seed$1.5M$57.1M1.00×
Small Pharma Ltd.Seed$1.9M$52.8M0.93×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$3.0M2020-06-29$15.1M$114.6M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$3.0M2020-06-29
    • First recorded raise — entered as Seed.
    • 6 investors on this round.
Intelligence
—
Modeled next raise
$4.8M
Modeled next size est.range $3.1M–$7.7M
—
Last step-up
—
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Todd Stottlemyre—3 other2020-06
Registry & provenance

Pharma-Labs Finance LLC is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1817082
SEC CIK
2020
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
BreStem Therapeutics, Inc.PharmaSeed$3.0M$68.9Msame sector · same stage
NeuroLambda Therapeutics, Inc.PharmaSeed$3.0M$14.5Msame sector · same stage
NV Therapeutics, Inc.PharmaSeed$3.0M$12.8Msame sector · same stage
Zeta Surgical Inc.PharmaSeed$3.1M$7.3Msame sector · same stage
Strategikon Pharma, Inc.PharmaSeed$3.3M$7.0Msame sector · same stage
Fitness Fingerprint Therapeutics, Inc.PharmaSeed$2.8M$6.4Msame sector · same stage
Antigenix Therapeutics, Inc.PharmaSeed$3.4M$8.1Msame sector · same stage
Capstone Therapeutics Corp.PharmaSeed$3.4M$130.9Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Small Pharma Financing Inc.PharmaSeries B$909.1M84%
Pharm, LLCOtherSeries A$107.4M83%
Psybio Therapeutics Financing Inc.PharmaSeries A$154.3M81%
Nextgen Pharma LlcPharmaSeries A$229.7M78%
Star Therapeutics LLCPharmaSeries D+$936.1M77%
Zoo Pharma Dynamics Inc.PharmaSeed$139.3M77%
Diligent Pharma, Inc.PharmaSeed$34.7M77%
Capstone Therapeutics Corp.PharmaSeed$130.9M77%
Frequently asked
How much funding has Pharma-Labs Finance LLC raised?
Pharma-Labs Finance LLC has raised approximately $3.0M in disclosed capital across 1 recorded financing round, aggregated from public filings.
What is Pharma-Labs Finance LLC's estimated valuation?
Provath's modeled valuation for Pharma-Labs Finance LLC is approximately $114.6M (modeled range $2.3M–$898.8M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Pharma-Labs Finance LLC at?
Pharma-Labs Finance LLC's latest modeled financing stage is Seed. Its most recent recorded round closed around Mon Jun 29.
What does Pharma-Labs Finance LLC do and where is it based?
Pharma-Labs Finance LLC operates in the Pharma sector, based in PHOENIX.
Explore related

See where Pharma-Labs Finance LLC sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Pharma-Labs Finance LLC, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.